"ROSSAmed HBsAg" is designed for qualitative and quantitative determination of the surface antigen (HBsAg) of hepatitis B virus (HBV) in human serum and plasma.
“ROSSAmed HBsAg” is designed for qualitative and quantitative determination of the surface antigen (HBsAg) of hepatitis B virus (HBV) in human serum and plasma by senzyme-linked immunosorbent assay (ELISA).
HBsAg is a glycosylated HBV envelope protein. HBsAg contains the determinant “a”, common to all subtypes of the virus, and additional subdeterminates (d and y), determining the immunological differences of subgroups (ad and au). Currently, it is the main marker in determining hepatitis B virus infection. HBV causes acute and chronic viral hepatitis and is more often transmitted by blood transfusion than other viral hepatitis. It causes a whole spectrum of manifestations, ranging from mild, asymptomatic form to lightning-fast hepatitis, serious liver damage and cirrhosis. In addition, the role of HBV in the development of primary liver cancer has been clearly proven.
Quantitative determination of HBsAg in the blood seems appropriate when correcting the diagnosis and selecting treatment. When screening for hepatitis B, a qualitative determination of HBsAg in the blood is sufficient.